Garda Capital Partners’s Biogen BIIB Stock Holding History

Garda Capital Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,579	Closed	-$340K	–	454
2024 Q1	$340K	Sell	1,579 -182	-10%	-$42.6K	0.01%	357
2023 Q4	$456K	Buy	1,761 +965	+121%	+$237K	0.04%	365
2023 Q3	$205K	Buy	+796	New	+$213K	0.01%	671
2023 Q2	–	Sell	-186	Closed	-$51.7K	–	350
2023 Q1	$51.7K	Buy	+186	New	+$51.5K	﹤0.01%	336

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Garda Capital Partners's BIIB Position: Q2 2024 in Review

Garda Capital Partners sold out of Biogen (BIIB) in Q2 2024, closing a stake of 1,579 shares — an estimated $340K sold.

Garda Capital Partners first reported a position in BIIB in Q1 2023 and held it in 4 quarters. The position peaked at $456K in Q4 2023. 943 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

Garda Capital Partners reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
Garda Capital Partners sold 1,579 Biogen shares in Q2 2024, an estimated $340K.
Garda Capital Partners first reported a position in Biogen in Q1 2023 and held it in 4 quarters.
Garda Capital Partners's Biogen position peaked at $456K in Q4 2023.
943 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on Garda Capital Partners's 13F filing for Q2 2024, filed 14 Aug 2024.